Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial.
Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial.
复制标题
DOI：
10.1002/acr.22285
复制
发表时间：
2014-08
影响因子：
4.7
通讯作者：
Massarotti, Elena
中科院分区：
文献类型：
--
作者：
Solomon, Daniel H.;Garg, Rajesh;Lu, Bing;Todd, Derrick J.;Mercer, Emileigh;Norton, Tabatha;Massarotti, Elena
Observational studies suggest that hydroxychloroquine (HCQ) may reduce the risk of developing diabetes mellitus in patients with RA. We examined the effect of HCQ on insulin resistance in non-diabetic subjects with stable RA. Twenty-three RA subjects not currently using HCQ completed a 16 week double blind cross-over study. Subjects were randomly allocated to receive HCQ (6.5 mg/kg per day) or placebo for the first 8 weeks followed by cross-over to the other arm for the final 8 weeks. Subjects underwent oral glucose tolerance testing and fasting lipid measurements at baseline, 8 and 16 weeks. The change (standard deviation) from baseline in insulin sensitivity index (ISI), insulin resistance (HOMA-IR), and lipid parameters were compared between placebo and HCQ using linear regression. The mean age was 56 years, with 96% females and the median body mass index was 26.0 kg/m2. After 8 weeks of HCQ, the ISI increased 0.4 (SD 2.9) compared with a small increase during placebo of 0.14 (SD 3.1) (adjusted p = 0.785), and HOMA-IR decreased 0.3 (SD 1.5) during HCQ versus a decrease of 0.42 (SD 1.4) during placebo (adjusted p = 0.308). Small decreases in total cholesterol (12.7mg/dl) and LDL cholesterol (12.4mg/dl) were observed during the HCQ treatment periods (both adjusted p < 0.05 compared to placebo). HCQ use for 8 weeks in non-diabetic patients with stable RA produced no significant change in insulin resistance. We observed small and statistically significant improvements in total and LDL cholesterol during HCQ treatment.
登录
查看更多内容
影响因子：
120.7
作者：
Solomon, Daniel H.;Massarotti, Elena;Schneeweiss, Sebastian
通讯作者：
Schneeweiss, Sebastian
影响因子：
2.6
作者：
FOX, RI;KANG, HI
通讯作者：
KANG, HI
影响因子：
2.1
作者：
Emami, J;Gerstein, HC;Jamali, F
通讯作者：
Jamali, F
影响因子：
8.2
作者：
MATTHEWS, DR;HOSKER, JP;TURNER, RC
通讯作者：
TURNER, RC
DOI：
10.1097/00124743-199702000-00002
发表时间：
1997-02-01
期刊：
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
影响因子：
--
作者：
Kavanaugh, A;Adams-Huet, B;McFarlin, J
通讯作者：
McFarlin, J